GIST announced a breakthrough in genetic diagnostics with a new platform capable of flexibly designing and detecting target genes across multiple diseases.
The technology addresses limitations of traditional PCR methods, which, while accurate, are time-consuming and require specialized equipment. It also improves on existing CRISPR-based diagnostics by eliminating the need to optimize conditions for each individual gene.
By controlling gene editing mechanisms, the platform enables universal detection of target genes. Researchers say it can be applied broadly, from infectious diseases like COVID-19 to various cancers, using a single system.
A key advantage is simplified design. Adjusting oligonucleotide configurations allows the same platform to be adapted for different conditions, significantly improving development efficiency.
The study was published in Nucleic Acids Research, highlighting its potential as a scalable diagnostic solution for a wide range of genetic and disease detection applications.
